The panel identifies—but does not establish—the hypothesis that cryoablation could offer local control or quality-of-life benefits in selected pediatric malignancies and aggressive benign diseases, potentially complementing systemic therapy or providing an alternative to surgery; prospective comparative studies are required to test efficacy, complications, and developmental toxicity.

Evidence in the record links the five-gene signature to prognosis, immune and stromal features, and computationally predicted sensitivity to entinostat and sapitinib; it may therefore support risk-adapted treatment selection or target discovery, but prospective prognostic validation and experimental or clinical confirmation of drug response are still required.

The evidence supports combining diagnostic genomic risk with end-of-induction MRD for relapse stratification; it is an inference, not tested here, that this strategy could guide treatment intensification, alternative therapy, or toxicity-sparing de-escalation and thereby improve outcomes.

The study provides evidence that non-contrast MRI can support AI-based prediction of brain tumour enhancement; it is an inference, not a demonstrated clinical outcome, that validated pediatric-specific use could reduce unnecessary gadolinium exposure or identify patients who should receive contrast during the same imaging visit.

The reported association suggests—but does not establish—that prioritizing enteral over parenteral nutrition during intensive AML induction could better preserve nutritional status; prospective controlled studies are needed to determine causality, safety, treatment-tolerance effects, and applicability to pediatric patients.

The evidence shows that centralized radiology, pathology, and surgical review can provide timely trial risk assignment for most eligible patients; it is reasonable but unproven to infer that improving submission and review bottlenecks could increase appropriate protocol enrollment and treatment selection.

The observed combination of substantial corticosteroid exposure and steroid-sparing immunosuppressant use in only about one-third of patients identifies a potential management gap; it may justify prospective testing of steroid-sparing strategies, but this descriptive study provides no evidence that such strategies improve efficacy, safety, or long-term outcomes.

The record supports TargetPrior as a hypothesis-generation and target-ranking tool; it remains an inference that its prioritized genes will identify effective therapies, improve relapse outcomes, or guide treatment selection because no functional target validation, drug testing, or clinical evaluation is reported.

The evidence supports the hypothesis that reducing avoidable pediatric low-dose ionizing radiation exposure could lower subsequent leukemia risk; however, this is an inference for cancer prevention and radiation protection, not evidence that a specific exposure-reduction intervention improves clinical outcomes.

The evidence establishes a population-level estimate of EBV-associated pediatric cancer burden but does not test an intervention; inferentially, the concentration of EBV positivity in specific cancers—especially nasopharyngeal cancer—could support research into EBV prevention, biomarkers, or virus-directed therapies.

The reported human observational evidence supports testing whether Heshu Xiaoji pills can improve progression-free survival when added to standard treatment for HBV-related hepatocellular carcinoma; any causal benefit, active constituent, biological mechanism, responsive subgroup, or relevance to pediatric liver cancer remains inferential and requires controlled validation.

The reported clinical evidence suggests that selective parenchyma-preserving surgery may reduce loss of pancreatic tissue in appropriately chosen children, while the inference requiring prospective validation is that procedure selection based on tumor location and ability to achieve clear margins can preserve long-term function without compromising oncologic control.